Nextech Invest

Nextech Invest is a global venture capital firm headquartered in Zurich, Switzerland, specializing in oncology therapeutics. The firm focuses on investing in emerging biotechnology companies worldwide, identifying transformative cancer medicines, and nurturing portfolio companies through critical moments of scientific validation and value creation. Their investment approach emphasizes bridging the translational gap by taking drug assets from early preclinical stages and building their value through high-quality clinical studies demonstrating clinical efficacy.

The firm's portfolio spans the United States and Europe, with investments ranging from company inception to crossover rounds. Nextech Invest's in-house team, supported by an active group of Science Partners, concentrates on identifying critical inflection points between early scientific validation and clinical proof-of-concept. They proactively identify new opportunities and support portfolio companies through each critical stage of drug development and company growth, aiming to deliver better outcomes for patients.

Nextech Invest has a history of successful investments in companies such as Agensys, Autolus, Ganymed, MacroGenics, Blueprint Medicines, Peloton Therapeutics, Jounce Therapeutics, Neon Therapeutics, Arrakis, Vividion, Arvinas, Kinnate, Kronos, Black Diamond, and Revolution Medicines. Their investment strategy includes taking board positions in portfolio companies and seeking exits within three years via trade sales. The firm is a longstanding member of leading networks in private equity, such as EVCA, SECA, and EVPA, and works closely with the Union for International Cancer Control (UICC).